Please use this identifier to cite or link to this item:
http://hdl.handle.net/2445/183848
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Aguilar-Recarte, David | - |
dc.contributor.author | Palomer Tarridas, Francesc Xavier | - |
dc.contributor.author | Wahli, Walter | - |
dc.contributor.author | Vázquez Carrera, Manuel | - |
dc.date.accessioned | 2022-03-08T11:54:55Z | - |
dc.date.available | 2022-03-08T11:54:55Z | - |
dc.date.issued | 2021-08-09 | - |
dc.identifier.issn | 1661-6596 | - |
dc.identifier.uri | http://hdl.handle.net/2445/183848 | - |
dc.description.abstract | The current treatment options for type 2 diabetes mellitus do not adequately control the disease in many patients. Consequently, there is a need for new drugs to prevent and treat type 2 diabetes mellitus. Among the new potential pharmacological strategies, activators of peroxisome proliferator-activated receptor (PPAR)β/δ show promise. Remarkably, most of the antidiabetic effects of PPARβ/δ agonists involve AMP-activated protein kinase (AMPK) activation. This review summarizes the recent mechanistic insights into the antidiabetic effects of the PPARβ/δ-AMPK pathway, including the upregulation of glucose uptake, muscle remodeling, enhanced fatty acid oxidation, and autophagy, as well as the inhibition of endoplasmic reticulum stress and inflammation. A better understanding of the mechanisms underlying the effects resulting from the PPARβ/δ-AMPK pathway may provide the basis for the development of new therapies in the prevention and treatment of insulin resistance and type 2 diabetes mellitus. | - |
dc.format.mimetype | application/pdf | - |
dc.language.iso | eng | - |
dc.publisher | MDPI | - |
dc.relation.isformatof | Reproducció del document publicat a: https://doi.org/10.3390/ijms22168555 | - |
dc.relation.ispartof | International Journal of Molecular Sciences, 2021, vol. 22, num. 16, p. 8555 | - |
dc.relation.uri | https://doi.org/10.3390/ijms22168555 | - |
dc.rights | cc-by (c) Aguilar-Recarte, David et al., 2021 | - |
dc.rights.uri | https://creativecommons.org/licenses/by/4.0/ | - |
dc.source | Articles publicats en revistes (Farmacologia, Toxicologia i Química Terapèutica) | - |
dc.subject.classification | Trastorns del metabolisme dels lípids | - |
dc.subject.classification | Àcids grassos | - |
dc.subject.classification | Receptors nuclears (Bioquímica) | - |
dc.subject.classification | Glucosa | - |
dc.subject.other | Lipid metabolism disorders | - |
dc.subject.other | Fatty acids | - |
dc.subject.other | Nuclear receptors (Biochemistry) | - |
dc.subject.other | Glucose | - |
dc.title | The PPARβ/δ-AMPK Connection in the Treatment of Insulin Resistance | - |
dc.type | info:eu-repo/semantics/article | - |
dc.type | info:eu-repo/semantics/publishedVersion | - |
dc.identifier.idgrec | 713706 | - |
dc.date.updated | 2022-03-08T11:54:55Z | - |
dc.rights.accessRights | info:eu-repo/semantics/openAccess | - |
Appears in Collections: | Articles publicats en revistes (Farmacologia, Toxicologia i Química Terapèutica) |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
713706.pdf | 1.53 MB | Adobe PDF | View/Open |
This item is licensed under a
Creative Commons License